61
Participants
Start Date
May 2, 2013
Primary Completion Date
June 7, 2017
Study Completion Date
June 7, 2017
Tremelimumab
3.5 mg/kg or 10 mg /kg intravenous (IV) every 4 weeks times 6 doses and then every 12 weeks for 2 years
RFA
Performed on Day 36
TACE
Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and every (q)6 months thereafter (if indicated)
Cryoablation
Performed on Day 36
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Cancer Institute (NCI)
NIH